C. David Nicholson Insider Trading $AGN Allergan plc
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for C. David Nicholson.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of C. David Nicholson. C. David Nicholson is Chief R&D Officer in Allergan plc ($AGN) and EVP Chief R&D Officer in Allergan plc ($AGN).
C. David Nicholson in Allergan plc
Trading Symbol: AGNIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of C. David Nicholson: EVP Chief R&D Officer, Chief R&D Officer
Holdings: 0 shares
Current Value: $0
Latest Transaction: May 11 2020
$AGN Market Capitalization: $87.25B
$AGN Previous Close: $234.43
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of C. David Nicholson in Allergan plc
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 11 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Option Exercise | D | 0.00 | 26,506 | 0 | 0 | |
May 11 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Option Exercise | D | 0.00 | 26,506 | 0 | 0 | |
May 11 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Option Exercise | D | 215.77 | 17,006 | 3,669,385 | 0 | |
May 11 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Option Exercise | D | 215.77 | 17,006 | 3,669,385 | 0 | |
May 11 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Sell | D | 0.00 | 25,201 | 0 | 0 | 25.2 K to 0 (-100.00 %) |
May 11 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Sell | D | 0.00 | 25,201 | 0 | 0 | 25.2 K to 0 (-100.00 %) |
May 11 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Sell | D | 0.00 | 9,999 | 0 | 0 | 10 K to 0 (-100.00 %) |
May 11 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Sell | D | 0.00 | 9,999 | 0 | 0 | 10 K to 0 (-100.00 %) |
Apr 07 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Grant | A | 193.84 | 21,667 | 4,199,931 | 35,972 | 14.3 K to 36 K (+151.46 %) |
Mar 04 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Grant | A | 193.84 | 21,667 | 4,199,931 | 35,972 | 14.3 K to 36 K (+151.46 %) |
Jan 02 2020 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Payment of Exercise | F | 191.17 | 1,031 | 197,096 | 14,305 | 15.3 K to 14.3 K (-6.72 %) |
Apr 05 2019 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Payment of Exercise | F | 145.71 | 871 | 126,913 | 15,336 | 16.2 K to 15.3 K (-5.37 %) |
Jan 03 2019 | AGN | Allergan plc | Nicholson C. David | EVP Chief R&D Offic ... | Payment of Exercise | F | 133.66 | 1,150 | 153,709 | 16,207 | 17.4 K to 16.2 K (-6.63 %) |
Apr 05 2018 | AGN | Allergan plc | Nicholson C. David | Chief R&D Officer | Payment of Exercise | F | 164.74 | 871 | 143,489 | 17,357 | 18.2 K to 17.4 K (-4.78 %) |
Jan 02 2018 | AGN | Allergan plc | Nicholson C. David | Chief R&D Officer | Payment of Exercise | F | 163.58 | 1,086 | 177,648 | 18,228 | 19.3 K to 18.2 K (-5.62 %) |
Oct 30 2017 | AGN | Allergan plc | Nicholson C. David | Chief R&D Officer | Option Exercise | M | 0.00 | 6,274 | 0 | 0 | |
Oct 30 2017 | AGN | Allergan plc | Nicholson C. David | Chief R&D Officer | Buy | M | 0.00 | 6,274 | 0 | 19,314 | 13 K to 19.3 K (+48.11 %) |
Aug 07 2017 | AGN | Allergan plc | Nicholson C. David | Chief R&D Officer | Payment of Exercise | F | 242.65 | 3,898 | 945,850 | 13,040 | 16.9 K to 13 K (-23.01 %) |
Apr 04 2017 | AGN | Allergan plc | Nicholson C. David | Chief R&D Officer | Grant | A | 237.68 | 8,835 | 2,099,903 | 16,938 | 8.1 K to 16.9 K (+109.03 %) |
Page: 1